1.646.889.1200|info@lifescipublicrelations.com

Chikungunya Vaccine Candidate Delivered Excellent Study Results

//Chikungunya Vaccine Candidate Delivered Excellent Study Results

Chikungunya Vaccine Candidate Delivered Excellent Study Results

Valneva chikungunya vaccine candidate VLA1553 was generally safe in all dose groups and the local tolerability profile was excellent.

By | 2019-11-18T12:33:43-04:00 November 18th, 2019|News|Comments Off on Chikungunya Vaccine Candidate Delivered Excellent Study Results

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.